By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho today lowered estimates on Qiagen, citing concerns about competition, higher cost assumptions, and an unsettled European market.

Separately, the bank also downgraded diagnostic firm Alere, citing expected cost increases stemming from the firm's molecular diagnostics ambitions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.